Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43925   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2016-002244-16
    Sponsor's Protocol Code Number:NRG-HN002
    National Competent Authority:Ireland - HPRA
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-07-06
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedIreland - HPRA
    A.2EudraCT number2016-002244-16
    A.3Full title of the trial
    A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A phase II clinical trial for patients with cancer of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls) that is non-smoking associated and is positive for the p16 biomarker.
    A.4.1Sponsor's protocol code numberNRG-HN002
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIrish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNRG Oncology
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIrish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    B.5.2Functional name of contact pointClinical Program Leader
    B.5.3 Address:
    B.5.3.1Street Address60 Fitzwilliam Square
    B.5.3.2Town/ cityDublin
    B.5.3.3Post code2
    B.5.4Telephone number+35316677211
    B.5.5Fax number+35316697869
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCisplatin
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCisplatin
    D.3.9.3Other descriptive nameCISPLATIN
    D.3.9.4EV Substance CodeSUB07483MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/m2 milligram(s)/square meter
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Locoregionally advanced oropharyngeal cancer
    E.1.1.1Medical condition in easily understood language
    Cancer of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10031096
    E.1.2Term Oropharyngeal cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Primary Objective:
    ● To select the arm(s) achieving a 2-year progression-free survival rate of ≥ 85% without unacceptable swallowing toxicity at 1 year.
    E.2.2Secondary objectives of the trial
    Secondary Objectives:
    ● To determine patterns of failure (locoregional relapse versus distant) and survival (overall and progression-free) at 6 months and 2 years;
    ● To determine acute toxicity profiles at the end of radiation therapy and at 1 and 6 months;
    ● To determine late toxicity profiles at 1 and 2 years;
    ● To determine patient-reported swallowing outcomes at 6 months and 1 and 2 years;
    ● To determine the predictive value of 12-14 week, post-treatment FDG-PET/CT for locoregional control and PFS at 2 years;
    ● To determine the predictive value of blood and tissue biomarkers for disease outcomes at 2 years;
    ● To determine swallowing recovery per videofluoroscopy imaging at 2 years.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    > Step 1: Registration

    1. Pathologically (histologically/cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma&basaloid squamous cell carcinoma) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation&should be sufficient to estimate the size of the primary (for T stage).

    2. Clinically or radiographically evident measurable disease at the primary site or at nodal stations. Tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving ≤ 4 nodes are permitted&considered as non-therapeutic nodal excisions.

    3. Immunohistochemical (IHC) staining for p16 must be performed on tissue&this tissue must be submitted for central review. Fine needle aspiration (FNA) biopsy specimens may be used as the sole diagnostic tissue if formalin-fixed paraffin-embedded cell block material is available for p16 IHC. FNA specimens prepared with adequate p16 testing in this manner are acceptable to submit for central review. If the p16 preparation is not adequate, additional specimens will be required to establish p16 status.

    4. Clinical stage T1-T2, N1-N2b or T3, N0-N2b (AJCC, 7th ed.) including no distant metastases based on the following diagnostic workup:
    ● General history&physical examination within 56 days prior to registration;
    ● Fiberoptic exam with laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 70 days prior to registration;
    ● One of the following combinations of imaging is required within 56 days prior to registration:
    a) A CT scan of the neck (with contrast) & a chest CT scan (with or without contrast);
    b) or an MRI of the neck (with contrast) & a chest CT scan (with or without contrast);
    c) or a CT scan of neck (with contrast) & a PET/CT of neck and chest (with or without contrast);
    d) or an MRI of the neck (with contrast) & a PET/CT of neck and chest (with or without contrast).
    Note: A CT scan of neck and/or a PET/CT performed for the purposes of radiation planning may serve as both staging&planning tools.

    5. Patients must provide their personal smoking history prior to registration. The lifetime cumulative history cannot exceed 10 pack-years. Please refer to the protocol for details of pack-years calculation.

    6. Zubrod Performance Status of 0-1 within 56 days prior to registration;

    7. Age ≥ 18;

    8. The trial is open to both genders;

    9. Adequate hematologic function within 14 days prior to registration, defined as follows:
    ● Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
    ● Platelets ≥ 100,000 cells/mm3;
    ● Hemoglobin ≥ 8.0 g/dl; Note: The use of transfusion or other intervention to achieve
    Hgb ≥ 8.0 g/dl is acceptable.

    10. Adequate renal function within 14 days prior to registration, defined as follows:
    ● Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula as described in protocol section 3.2.10.

    11. Adequate hepatic function within 14 days prior to registration defined as follows:
    ● Bilirubin < 2 mg/dl;
    ● AST or ALT < 3 x the upper limit of normal.

    12. Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential;

    13. Patients who are HIV positive but have no prior AIDS-defining illness&have CD4 cells of at least 350/mm3 are eligible. HIV-positive patients must not have multi-drug resistant HIV infection or other concurrent AIDS-defining conditions. Patients must not be sero-positive for Hepatitis B (Hepatitis B surface antigen positive or antihepatitis B core antigen positive) or sero-positive for Hepatitis C (anti-Hepatitis C antibody positive). However, patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B).

    14. The patient must provide study-specific informed consent prior to study entry, including consent for mandatory submission of tissue for required, central p16 review.

    15.Patients who speak English (or read one of the languages for which a translation is available (see protocol Section 10.2) must consent to complete the mandatory dysphagia-related patient reported instrument (MDADI). Please refer to the protocol section 3.2.15 for additional details.

    > Step 2: Randomization

    16. p16 positive by immunohistochemistry (defined as greater than 70% strong nuclear or nuclear&cytoplasmic staining of tumor cells), confirmed by central pathology review; (see protocol Section 10.1 for details).
    E.4Principal exclusion criteria
    > Step 1: Registration

    1. Cancers considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), or the nasopharynx, hypopharynx, or larynx, even if p16 positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas;

    2. Carcinoma of the neck of unknown primary site origin (even if p16 positive);

    3. Radiographically matted nodes, defined as 3 abutting nodes with loss of the intervening fat plane;

    4. Supraclavicular nodes, defined as nodes visualized on the same axial imaging slice as the clavicle;

    5. Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles;

    6. Gross total excision of both primary and nodal disease with curative intent; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. In other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed.

    7. Patients with simultaneous primary cancers or separate bilateral primary tumor sites are excluded with the exception of patients with bilateral tonsil cancers;

    8. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible);

    9. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable;

    10. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;

    11. Severe, active co-morbidity defined as follows:
    ● Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
    ● Transmural myocardial infarction within the last 6 months;
    ● Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
    ● Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration;
    ● Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol other than those requested in protocol section 3.2.10.
    ● Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition with immune compromise greater than that noted in protocol section 3.1.13; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements
    may also exclude immuno-compromised patients.

    12. Pregnancy; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.

    13. Prior allergic reaction to cisplatin.
    E.5 End points
    E.5.1Primary end point(s)
    Progression-free survival (PFS) at 2 years.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Progression free survival (PFS) is defined as from time of randomization to local-regional failure, distant metastasis or deaths due to any causes. PFS rates will be estimated for all treatment arms using the Kaplan-Meier method (1958).One sample binomial test will be used to test the 2-year PFS for each arm. Multivariate analysis will be performed using the Cox proportional hazards model.

    The interim analysis time will be 1.56 years from the start of study (6 months for site IRB approval,0.56 years for accrual,6-month follow up).

    Interim reports (containing information about accrual rate,pretreatment characteristics of patients accrued&the frequency&severity of adverse events) will be prepared biannually until the final analysis has been accepted for presentation or publication.
    E.5.2Secondary end point(s)
    ● Local-regional failure at 6 months and 2 years;
    ● Distant metastasis at 6 months and 2 years;
    ● Overall survival at 6 months and 2 years;
    ● Acute toxicities (≥ grade 3, CTCAE, v. 4) at the end of radiation therapy and at 1 and 6 months;
    ● Late toxicities at (≥ grade 3, CTCAE, v. 4) 1 and 2 years;
    ● Patient-reported swallowing outcomes at 6 months and 1 and 2 years;
    ● Post-treatment FDG-PET/CT;
    ● Translational research.
    E.5.2.1Timepoint(s) of evaluation of this end point
    For the secondary endpoints listed in protocol section 13.2.2, OS rates will be estimated using the Kaplan-Meier method (1958) and the failure rates for the experimental treatment will be compared against the control using a log rank test. The cumulative incidence method will be used to estimate locoregional and distant failure rates and the failure rates for the experimental treatment will be compared against the control using a failure specific log rank test. Failure for local-regional failure and distant metastasis endpoints is defined in protocol section 13.6.1.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E. description
    Radiotherapy plus Chemotherapy vs Radiotherapy alone
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 6
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 6
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 12
    F.4.2.2In the whole clinical trial 296
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will be treated according to standard after care per institutional guidelines.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-09-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-09-12
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands